Novartis AG
NYSE:NVS

Watchlist Manager
Novartis AG Logo
Novartis AG
NYSE:NVS
Watchlist
Price: 143.2 USD 0.65%
Market Cap: 289.9B USD

Relative Value

The Relative Value of one NVS stock under the Base Case scenario is hidden USD. Compared to the current market price of 143.2 USD, Novartis AG is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NVS Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
1
vs Industry
29
Median 3Y
4.3
Median 5Y
4.1
Industry
2.6
Forward
4.9
vs History
34
vs Industry
26
Median 3Y
17.4
Median 5Y
17.2
Industry
21.4
Forward
15.7
vs History
22
vs Industry
32
Median 3Y
12.4
Median 5Y
12
Industry
16.4
vs History
53
vs Industry
27
Median 3Y
18.3
Median 5Y
19.5
Industry
22.8
vs History
0
vs Industry
13
Median 3Y
5
Median 5Y
3.7
Industry
2.2
vs History
1
vs Industry
26
Median 3Y
4.5
Median 5Y
4.2
Industry
2.9
Forward
5.1
vs History
3
vs Industry
34
Median 3Y
6
Median 5Y
5.9
Industry
5.5
vs History
15
vs Industry
30
Median 3Y
10.8
Median 5Y
10.4
Industry
13
Forward
12.2
vs History
57
vs Industry
29
Median 3Y
15.9
Median 5Y
15.7
Industry
16.5
Forward
13.6
vs History
30
vs Industry
30
Median 3Y
12.9
Median 5Y
12.6
Industry
15.6
vs History
30
vs Industry
25
Median 3Y
15.8
Median 5Y
15.7
Industry
18.7
vs History
0
vs Industry
26
Median 3Y
2.6
Median 5Y
2.1
Industry
1.9

Multiples Across Competitors

NVS Competitors Multiples
Novartis AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Novartis AG
NYSE:NVS
218.3B USD 4.9 19.1 12.1 15.6
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 56.7 38 40.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
499.2B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
267.7B CHF 4.3 28.4 12.1 14.1
UK
AstraZeneca PLC
LSE:AZN
220.3B GBP 5.1 31.6 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
276B USD 4.3 14.5 10.3 12.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.9 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.6 10.3
FR
Sanofi SA
PAR:SAN
100.4B EUR 1.5 7.3 6.6 6.6
P/E Multiple
Earnings Growth PEG
CH
Novartis AG
NYSE:NVS
Average P/E: 23.1
19.1
17%
1.1
US
Eli Lilly and Co
NYSE:LLY
56.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.6
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
FR
Sanofi SA
PAR:SAN
7.3
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Novartis AG
NYSE:NVS
Average EV/EBITDA: 400.7
12.1
6%
2
US
Eli Lilly and Co
NYSE:LLY
38
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.1
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.6
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Novartis AG
NYSE:NVS
Average EV/EBIT: 1 713.1
15.6
12%
1.3
US
Eli Lilly and Co
NYSE:LLY
40.7
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.1
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
6.6
15%
0.4